We are pleased to see this litigation moving ahead so expeditiously, and look forward to the Status Conference next month.
New York, New York (PRWEB) December 29, 2012
Pradaxa lawsuits continue to move forward in the federal multidistrict litigation now underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to the court’s calendar, the next Status Conference in the litigation is scheduled for January 14, 2013 at 3:00 p.m. According to Case Management Order Number 11, Judge David Herndon has scheduled the Pradaxa litigation’s first trial for August 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“We are pleased to see this litigation moving ahead so expeditiously, and look forward to the Status Conference next month,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free lawsuit evaluations to alleged victims of Pradaxa bleeding.
Pradaxa, which is used to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation, was approved by the U.S. Food & Drug Administration (FDA) in October 2010. According to a recent article from Bloomberg.com, internal bleeding is a potential Pradaxa side effect for which there is no readily available antidote. Among other things, Bloomberg stated that the FDA had received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.*
On December 19th, the FDA issued a Drug Safety Communication announcing a new contraindication was being added to the Pradaxa label to warn against its use in patients with mechanical heart valves. The FDA ordered Boehringer Ingelheim to add the contraindication after the RE-ALIGN trial was halted. The study ended early when it was found that Pradaxa users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of warfarin. There was also more Pradaxa bleeding reported after valve surgery compared to warfarin bleeding, the FDA said.**
All of the complaints pending in the Southern District of Illinois allege plaintiffs suffered serious, life-threatening episodes of Pradaxa bleeding, and that Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients.
Victims of serious Pradaxa side effects may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more about filing a Pradaxa lawsuit, please visit our website http://www.consumerinjurylawyers.com/, or call 1-877-779-1414 to speak with one of our attorneys today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com